BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

467 related articles for article (PubMed ID: 28103574)

  • 1. 68Ga-PSMA-11 PET/CT for prostate cancer staging and risk stratification in Chinese patients.
    Zang S; Shao G; Cui C; Li TN; Huang Y; Yao X; Fan Q; Chen Z; Du J; Jia R; Sun H; Hua Z; Tang J; Wang F
    Oncotarget; 2017 Feb; 8(7):12247-12258. PubMed ID: 28103574
    [TBL] [Abstract][Full Text] [Related]  

  • 2. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 3. How accurate is
    Erdem S; Simsek DH; Degirmenci E; Aydin R; Bagbudar S; Ozluk Y; Sanli Y; Sanli O; Ozcan F
    Urol Oncol; 2022 Jan; 40(1):6.e1-6.e9. PubMed ID: 34400066
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    Klingenberg S; Jochumsen MR; Ulhøi BP; Fredsøe J; Sørensen KD; Borre M; Bouchelouche K
    J Nucl Med; 2021 Feb; 62(2):214-220. PubMed ID: 32444374
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Primary lymph-node staging with
    Corona-Montes VE; González-Cuenca E; Fernández-Noyola G; Olarte-Casas MA; Bobadilla-Salazar D; Medrano-Urtecho HM; Asimakopoulos AD
    Urol Oncol; 2021 Aug; 39(8):494.e1-494.e6. PubMed ID: 33223371
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical utility of [68Ga]Ga-PSMA-11 PET/CT in initial staging of patients with prostate cancer and importance of intraprostatic SUVmax values.
    Rogic I; Golubic AT; Zuvic M; Smitran T; Jukic N; Gamulin M; Kastelan Z; Huic D
    Nucl Med Rev Cent East Eur; 2024; 27(0):6-12. PubMed ID: 38680016
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lymph node staging with 68Ga-PSMA PET in patients with intermediate and high-risk prostate cancer suitable for radical prostatectomy managed in a prostate cancer unit.
    Maestroni UV; Campobasso D; Guarino G; Acampora A; Scarlattei M; Ziglioli F; Dinale F; Baldari G; Migliari S; Gasparro D; Ferretti S; Silini EM; Ruffini L
    Chin Clin Oncol; 2023 Jun; 12(3):22. PubMed ID: 37417288
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospective evaluation of 68Gallium-prostate-specific membrane antigen positron emission tomography/computed tomography for preoperative lymph node staging in prostate cancer.
    van Leeuwen PJ; Emmett L; Ho B; Delprado W; Ting F; Nguyen Q; Stricker PD
    BJU Int; 2017 Feb; 119(2):209-215. PubMed ID: 27207581
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of
    Schwenck J; Rempp H; Reischl G; Kruck S; Stenzl A; Nikolaou K; Pfannenberg C; la Fougère C
    Eur J Nucl Med Mol Imaging; 2017 Jan; 44(1):92-101. PubMed ID: 27557844
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is there a utility of adding skeletal imaging to 68-Ga-prostate-specific membrane antigen-PET/computed tomography in initial staging of patients with high-risk prostate cancer?
    Raju S; Sharma A; Patel C; Sahoo R; Das CJ; Kumar S; Sharma A; Kumar R
    Nucl Med Commun; 2020 Nov; 41(11):1183-1188. PubMed ID: 32796451
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The meta-analysis of the effect of 68Ga-PSMA-PET/CT diagnosis of prostatic cancer compared with bone scan.
    Zhao R; Li Y; Nie L; Qin K; Zhang H; Shi H
    Medicine (Baltimore); 2021 Apr; 100(15):e25417. PubMed ID: 33847640
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of
    Regula N; Kostaras V; Johansson S; Trampal C; Lindström E; Lubberink M; Velikyan I; Sörensen J
    Sci Rep; 2020 Mar; 10(1):4993. PubMed ID: 32193430
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Accuracy of 68Ga-PSMA PET-CT and PET-MRI in lymph node staging for localized prostate cancer.
    Barbosa ÁRG; Amaral BS; Lourenço DB; Bianco B; Gushiken FA; Apezzato M; Silva JF; Cunha MLD; Filippi RZ; Baroni RH; Lemos GC; Carneiro A
    Einstein (Sao Paulo); 2022; 20():eAO6599. PubMed ID: 35584444
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnostic Accuracy of
    Satapathy S; Singh H; Kumar R; Mittal BR
    AJR Am J Roentgenol; 2021 Mar; 216(3):599-607. PubMed ID: 32755196
    [No Abstract]   [Full Text] [Related]  

  • 15. Potential Impact of
    Calais J; Kishan AU; Cao M; Fendler WP; Eiber M; Herrmann K; Ceci F; Reiter RE; Rettig MB; Hegde JV; Shaverdian N; King CR; Steinberg ML; Czernin J; Nickols NG
    J Nucl Med; 2018 Nov; 59(11):1714-1721. PubMed ID: 29653978
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    Hruby G; Eade T; Emmett L; Ho B; Hsiao E; Schembri G; Guo L; Kwong C; Hunter J; Byrne K; Kneebone A
    Asia Pac J Clin Oncol; 2018 Aug; 14(4):343-346. PubMed ID: 29663686
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 68Ga-PSMA PET/CT in prostate cancer patients - patterns of disease, benign findings and pitfalls.
    Keidar Z; Gill R; Goshen E; Israel O; Davidson T; Morgulis M; Pirmisashvili N; Ben-Haim S
    Cancer Imaging; 2018 Nov; 18(1):39. PubMed ID: 30382889
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 68Ga-PSMA-11 PET/CT in Newly Diagnosed Prostate Adenocarcinoma.
    Ergül N; Yilmaz Güneş B; Yücetaş U; Toktaş MG; Çermik TF
    Clin Nucl Med; 2018 Dec; 43(12):e422-e427. PubMed ID: 30273204
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of 68Ga-PSMA-I/T PET-CT and Multiparametric MRI for Locoregional Staging of Prostate Cancer Patients: A Pilot Study.
    Çelen S; Gültekin A; Özlülerden Y; Mete A; Sağtaş E; Ufuk F; Yüksel D; Yağcı B; Zümrütbaş AE
    Urol Int; 2020; 104(9-10):684-691. PubMed ID: 32750695
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    Lengana T; Lawal IO; Boshomane TG; Popoola GO; Mokoala KMG; Moshokoa E; Maes A; Mokgoro NP; Van de Wiele C; Vorster M; Sathekge MM
    Clin Genitourin Cancer; 2018 Oct; 16(5):392-401. PubMed ID: 30120038
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.